KRAS / RAS targeting: from platform to Phase 3
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
VS-7375 (GFH375), a non-covalent dual ON/OFF KRAS G12D inhibitor, displays superior activity to ON-only #KRAS G12D inhibitors in preclinical models of pancreatic cancer #AACR26
@PanCAN
@EileenMOReilly
@Aiims1742
@MPishvaian
@AACR
@letswinpc
http://
verastem.com/wp-content/upl
oads/2026/04/AACR_2026_Poster_BLM_Final.pdf
…
Heat 12 · 8 likes · 1 reply · 3 reposts
Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter
Read the abstract →Ryan D. Mouery, Kristina Drizyte-Miller, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der
Read the abstract →Brandon L. Mouery, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der
Read the abstract →Source: CrozrX · x.com